AXL and sarcoma: Characterization of AXL genomic alterations, either point mutations or copy number alterations (amplifications) in sarcomas, including MFS, has been limited.4,7 To assess the role of AXL abnormalities in MFS, we sought to characterize the genomics of AXL across sarcoma types.